Fasting insulin levels correlate with the frequency of hypoglycemic events in people with type 2 diabetes on treatment with sulfonylureas: A pilot study

Indian J Pharmacol. 2020 Jan-Feb;52(1):44-48. doi: 10.4103/ijp.IJP_80_19. Epub 2020 Mar 11.

Abstract

Aims and objectives: We aimed to explore whether fasting insulin levels correlate with the risk of hypoglycemia in people with Type 2 diabetes (T2D) receiving sulfonylureas (SUs).

Materials and methods: Our study included 58 individuals with T2D who had been on treatment with SUs, but not insulin, for more than 2 years. Confirmed hypoglycemic episodes during the past year were self-reported by the patients, and a potential relationship of hypoglycemic event frequency with fasting insulin levels was investigated.

Results: Fasting insulin concentrations were found to have a low positive and statistically significant correlation with the number of cases of mild hypoglycemia per year (ρ = 0.279/P = 0.034) and a moderately positive and statistically significant correlation with the number of severe hypoglycemic events per month (ρ = 0.349/P = 0.007) and per year (ρ = 0.39/P = 0.002).

Conclusion: Our results suggest that fasting insulin levels might be a predictor of the risk of hypoglycemia in people with T2D on treatment with SUs.

Keywords: Fasting insulin; hypoglycemia; sulfonylureas; type 2 diabetes.

MeSH terms

  • Aged
  • Diabetes Mellitus, Type 2 / blood*
  • Diabetes Mellitus, Type 2 / drug therapy
  • Fasting / blood*
  • Female
  • Gliclazide / adverse effects*
  • Humans
  • Hypoglycemia / blood
  • Hypoglycemia / chemically induced*
  • Hypoglycemic Agents / adverse effects*
  • Insulin / blood*
  • Male
  • Middle Aged
  • Pilot Projects
  • Sulfonylurea Compounds / adverse effects*

Substances

  • Hypoglycemic Agents
  • Insulin
  • Sulfonylurea Compounds
  • glimepiride
  • Gliclazide